These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37957137)

  • 1. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists.
    Kerr KM; Bubendorf L; Lopez-Rios F; Khalil F; Roy-Chowdhuri S; Joubert P; Hartmann A; Guerini-Rocco E; Yatabe Y; Hofman P; Cooper WA; Dacic S
    Histopathology; 2024 Feb; 84(3):429-439. PubMed ID: 37957137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
    Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
    Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
    Gosney JR; Paz-Ares L; Jänne P; Kerr KM; Leighl NB; Lozano MD; Malapelle U; Mok T; Sheffield BS; Tufman A; Wistuba II; Peters S
    ESMO Open; 2023 Aug; 8(4):101587. PubMed ID: 37356358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
    Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
    J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
    Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
    Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
    Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer biomarkers: present status and future developments.
    Cagle PT; Allen TC; Olsen RJ
    Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
    Ionescu DN; Stockley TL; Banerji S; Couture C; Mather CA; Xu Z; Blais N; Cheema PK; Chu QS; Melosky B; Leighl NB
    Curr Oncol; 2022 Jul; 29(7):4981-4997. PubMed ID: 35877256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.
    Murgu S; Colt H
    Clin Lung Cancer; 2013 Nov; 14(6):609-26. PubMed ID: 24188629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
    Nesline MK; Knight T; Colman S; Patel K
    Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
    Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
    Sabari JK; Santini F; Bergagnini I; Lai WV; Arbour KC; Drilon A
    Curr Oncol Rep; 2017 Apr; 19(4):24. PubMed ID: 28303491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
    Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
    Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.